HOLY CROSS HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $10.4M
- Transactions
- 1,998
- Companies
- 40
- Average per transaction
- $5,185
Who reported the payments
| Gilead | $1,465,688 |
| Merck | $1,437,042 |
| AstraZeneca | $1,286,779 |
| Tesaro, Inc. | $1,146,918 |
| Boehringer Ingelheim | $365,550 |
| Eli Lilly | $360,578 |
| Novartis | $321,348 |
| Genentech, Inc. | $284,884 |
| Pfizer | $255,784 |
| EMD Serono, Inc. | $221,669 |
| Janssen Research & Development, LLC | $207,350 |
| Smith+Nephew | $203,695 |
| Viiv Healthcare Company | $200,000 |
| Orthofix Medical, Inc. | $199,905 |
| Stryker | $177,191 |
| E.r. Squibb & Sons, L.L.C. | $148,846 |
| Biogen | $126,873 |
| Hoffmann-la Roche Limited | $124,211 |
| Portola Pharmaceuticals, LLC | $116,004 |
| Orion Corporation | $108,711 |
| Boston Scientific | $104,725 |
| Medtronic | $99,204 |
| Abbott | $85,868 |
| F. Hoffmann-la Roche AG | $82,647 |
| UCB SA | $81,622 |
| CSL Behring | $75,651 |
| Astrazeneca UK Limited | $75,551 |
| Encore Medical, LP | $71,250 |
| Cvrx, Inc. | $64,573 |
| Daiichi Sankyo Inc. | $64,508 |
| Tolmar, Inc. | $48,293 |
| AbbVie | $46,368 |
| Nevro Corp. | $44,903 |
| Seagen Inc. | $44,407 |
| Zimmer Biomet | $41,403 |
| Otsuka Pharmaceutical Co., Ltd. | $36,205 |
| GSK | $35,502 |
| Olympus America Inc. | $35,386 |
| Genmab U.S., Inc. | $35,000 |
| Bristol Myers Squibb | $27,972 |